Cargando…

Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option

Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shuqi, Dong, Ning, Yang, Ming, Wang, Jialin, Feng, Xue, Wang, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346298/
https://www.ncbi.nlm.nih.gov/pubmed/34368372
http://dx.doi.org/10.1155/2021/9945725
_version_ 1783734837602942976
author Qin, Shuqi
Dong, Ning
Yang, Ming
Wang, Jialin
Feng, Xue
Wang, Yanling
author_facet Qin, Shuqi
Dong, Ning
Yang, Ming
Wang, Jialin
Feng, Xue
Wang, Yanling
author_sort Qin, Shuqi
collection PubMed
description Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD.
format Online
Article
Text
id pubmed-8346298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-83462982021-08-07 Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option Qin, Shuqi Dong, Ning Yang, Ming Wang, Jialin Feng, Xue Wang, Yanling J Immunol Res Review Article Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD. Hindawi 2021-07-29 /pmc/articles/PMC8346298/ /pubmed/34368372 http://dx.doi.org/10.1155/2021/9945725 Text en Copyright © 2021 Shuqi Qin et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Qin, Shuqi
Dong, Ning
Yang, Ming
Wang, Jialin
Feng, Xue
Wang, Yanling
Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
title Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
title_full Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
title_fullStr Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
title_full_unstemmed Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
title_short Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
title_sort complement inhibitors in age-related macular degeneration: a potential therapeutic option
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346298/
https://www.ncbi.nlm.nih.gov/pubmed/34368372
http://dx.doi.org/10.1155/2021/9945725
work_keys_str_mv AT qinshuqi complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption
AT dongning complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption
AT yangming complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption
AT wangjialin complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption
AT fengxue complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption
AT wangyanling complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption